Intellia Receives FDA Nod to Start Testing Crispr Therapy (2)

Intellia Therapeutics Inc. got regulators’ green light to start US trials of its gene-editing treatment for a rare swelling disorder, a major step forward for the biotechnology company that sent the shares climbing the most in two months.

The Food and Drug Administration cleared Intellia’s request to start human trials of its Crispr therapy for hereditary angioedema, according to a statement Thursday. The step is largely seen as procedural, but it’s becoming less of a guarantee and a bigger milestone for novel drugs like Intellia’s that aim to make permanent changes to a person’s DNA.

The Cambridge, Massachusetts based company’s ...